What’s Illumina, Inc. Upside After Today’s Bearish Options Activity?

 What's Illumina, Inc. Upside After Today's Bearish Options Activity?

In today’s session Illumina, Inc. (ILMN) recorded an unusually high (321) contracts volume of put trades. Someone, most probably a professional was a very active buyer of the December, 2016 put, expecting serious ILMN decrease. With 321 contracts traded and 12484 open interest for the Dec, 16 contract, it seems this is a quite bearish bet. The option with symbol: ILMN161216P00130000 closed last at: $2.15 or 6.5% down. About 524,855 shares traded hands. Illumina, Inc. (NASDAQ:ILMN) has declined 1.92% since April 28, 2016 and is downtrending. It has underperformed by 7.85% the S&P500.

Analysts await Illumina, Inc. (NASDAQ:ILMN) to report earnings on February, 7. They expect $0.81 EPS, 0.00% or $0.00 from last year’s $0.81 per share. ILMN’s profit will be $116.04 million for 40.03 P/E if the $0.81 EPS becomes a reality. After $0.97 actual EPS reported by Illumina, Inc. for the previous quarter, Wall Street now forecasts -16.49% negative EPS growth.

Illumina, Inc. (NASDAQ:ILMN) Ratings Coverage

Out of 23 analysts covering Illumina Inc (NASDAQ:ILMN), 7 rate it a “Buy”, 2 “Sell”, while 14 “Hold”. This means 30% are positive. $250 is the highest target while $116 is the lowest. The $170.80 average target is 31.70% above today’s ($129.69) stock price. Illumina Inc has been the topic of 47 analyst reports since July 22, 2015 according to StockzIntelligence Inc. The stock of Illumina, Inc. (NASDAQ:ILMN) has “Buy” rating given on Thursday, August 20 by BTIG Research. The stock of Illumina, Inc. (NASDAQ:ILMN) has “Overweight” rating given on Tuesday, October 6 by Piper Jaffray. Cowen & Co maintained it with “Outperform” rating and $180 target price in Tuesday, April 19 report. Deutsche Bank initiated Illumina, Inc. (NASDAQ:ILMN) rating on Thursday, January 7. Deutsche Bank has “Hold” rating and $192 price target. The rating was downgraded by First Analysis on Wednesday, November 2 to “Underweight”. Stifel Nicolaus maintained it with “Buy” rating and $175 target price in Tuesday, October 6 report. The rating was downgraded by Wells Fargo to “Market Perform” on Thursday, January 7. The company was reinitiated on Thursday, November 10 by Leerink Swann. Citigroup upgraded Illumina, Inc. (NASDAQ:ILMN) on Wednesday, August 26 to “Focus List” rating. The company was maintained on Monday, December 21 by Stifel Nicolaus.

According to Zacks Investment Research, “Illumina Inc. is a leading developer of next-generation tools for the large-scale analysis of genetic variation and function. The company’s tools will provide information that could be used to improve drugs and therapies, customize diagnoses and treatment, and cure disease. The company is developing a comprehensive line of products that can address the scale of experimentation and the breadth of functional analysis required to achieve the goals of molecular medicine.”

Insitutional Activity: The institutional sentiment decreased to 1.07 in Q2 2016. Its down 0.03, from 1.1 in 2016Q1. The ratio fall, as 66 funds sold all Illumina, Inc. shares owned while 150 reduced positions. 46 funds bought stakes while 191 increased positions. They now own 137.98 million shares or 3.82% less from 143.46 million shares in 2016Q1.
Alps Advsrs holds 0% or 3,566 shares in its portfolio. Lmr Ltd Liability Partnership owns 3,354 shares or 0.07% of their US portfolio. Moreover, Teacher Retirement Sys Of Texas has 0.12% invested in Illumina, Inc. (NASDAQ:ILMN) for 123,121 shares. Canada Pension Plan Investment Board reported 20,622 shares or 0.01% of all its holdings. Fiera owns 105,731 shares or 0.08% of their US portfolio. The Switzerland-based Gam Ag has invested 0.02% in Illumina, Inc. (NASDAQ:ILMN). Quantitative Investment Mgmt Ltd Limited Liability Company holds 14,200 shares or 0.09% of its portfolio. Bnp Paribas Arbitrage has 0.03% invested in the company for 41,098 shares. Jpmorgan Chase And has 0.22% invested in the company for 6.36M shares. Alpine Woods Investors Ltd Liability reported 32,500 shares or 0.27% of all its holdings. Royal Financial Bank Of Canada reported 60,979 shares or 0.01% of all its holdings. Tiverton Asset Mgmt Llc last reported 44,202 shares in the company. Cambridge Research has invested 0.01% of its portfolio in Illumina, Inc. (NASDAQ:ILMN). British Columbia Inv accumulated 76,733 shares or 0.09% of the stock. Bluestein R H & Com has invested 0.02% of its portfolio in Illumina, Inc. (NASDAQ:ILMN).

Insider Transactions: Since June 13, 2016, the stock had 0 insider buys, and 24 insider sales for $15.18 million net activity. 10,000 shares were sold by FLATLEY JAY T, worth $1.50M. On Tuesday, September 20 the insider EPSTEIN ROBERT S sold $52,287. The insider Dadswell Charles sold 116 shares worth $19,489. BOWMAN A BLAINE sold 5,000 shares worth $675,388. Shares for $668,880 were sold by WHITFIELD ROY A on Friday, August 12. Shares for $81,803 were sold by BRADBURY DANIEL on Monday, November 14. 716 shares were sold by HENRY CHRISTIAN O, worth $101,593.

Illumina, Inc. offers sequencing and array solutions for genetic analysis. The company has a market cap of $18.58 billion. The Company’s services and products serve clients in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. It has a 43.36 P/E ratio. The Company’s clients include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies.

ILMN Company Profile

Illumina, Inc. (Illumina), incorporated on May 16, 2000, offers sequencing and array solutions for genetic analysis. The Company’s services and products serve clients in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company’s clients include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies. Illumina provides sample-to-answer solutions to its clients in various areas of translational and clinical genomics, such as reproductive and genetic health, and oncology. Illumina provides reproductive-health solutions, including preimplantation genetic screening and diagnosis (PGS and PGD), noninvasive prenatal testing (NIPT), and neonatal and genetic health testing. The Company’s BaseSpace platform, which can be hosted onsite or in the cloud, integrates directly with its sequencing instruments, facilitates data sharing, provides data-storage solutions and streamlines analysis. It has activities in the United States, Europe, Asia-Pacific and other markets.

More recent Illumina, Inc. (NASDAQ:ILMN) news were published by: Fool.com which released: “Is Illumina Inc. a Buffett Stock?” on November 08, 2016. Also Fool.com published the news titled: “Illumina Inc. Is Floundering: Here’s What Management Had to Say” on November 04, 2016. Fool.com‘s news article titled: “Illumina Inc. Q3 Weighed Down by Sluggish High-Throughput System Sales” with publication date: November 02, 2016 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment